Concomitant Treatment Of Chronic Hepatitis C With Direct-Acting Antivirals And Multidrug-Resistant Tuberculosis Is Effective And Safe

Nara Melikyan,Helena Huerga,Hakob Atshemyan,Ohanna Kirakosyan, Narina Sargsyants, Tsovinar Aydinyan, Nora Saribekyan, Naira Khachatryan,Izabella Oganezova, Joana Falcao,Suna Balkan,Cathy Hewison

OPEN FORUM INFECTIOUS DISEASES（2021）

引用 8|浏览9

暂无评分

摘要

We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.

查看译文

关键词

chronic hepatitis C virus, direct-acting antiviral drugs, multidrug-resistant tuberculosis, sofosbuvir

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要